

TRANSPLANTATION AND CELLULAR ENGINEERING

Establishing a cord blood banking and transplantation program in Mexico: a single institution experience

Barbara Novelo-Garza, Alejandro Limon-Flores, Angel Guerra-Marquez, Fernando Luna-Bautista, Luis Juan-Shum, Ines Montero, Elizabeth Sanchez-Valle, Maria Antonieta Vélez-Ruelas, and Hector Mayani

BACKGROUND: Over the past decade, umbilical cord blood (UCB) banking and transplantation have increased significantly worldwide. The experience in developing countries, however, is still limited. In January 2005 the Mexican Institute of Social Security (IMSS) initiated its UCB banking and transplantation program. This study reports on the experience generated at this institution during the first 2 years of activities.

STUDY DESIGN AND METHODS: A public UCB bank was established at La Raza Medical Center, IMSS, in Mexico City. Good manufacturing practices and standard operating procedures were used to address donor selection, as well as UCB collection, processing, and cryopreservation. Based mainly on HLA and total nucleated cell (TNC) content, specific UCB units were thawed, processed, and released for transplantation.

RESULTS: Based on stringent selection criteria, 360 UCB units were collected from January 2005 to December 2006. A total of 201 (56%) units (minimum volume, 50 mL without anticoagulant) were processed and stored. Median values for specific parameters were as follows: volume, 89.9 mL; viability, 94.8%; TNCs, 0.91×10^9 ; CD34+ cells, 3.13×10^6 ; and colony-forming cells, 1.20×10^6 . During this period, 10 units had been released for transplantation to seven patients (six children and one adult). Engraftment was observed in five patients; four of them were still in remission (114-293 days after transplant). In spite of showing sustained engraftment, one patient died on Day +88. Two patients showed no engraftment and died 29 to 30 days after transplant.

CONCLUSION: The results obtained during this initial period are encouraging and indicate that the UCB banking and transplantation program at IMSS will help to improve already existing hematopoietic cell transplant programs in Mexico. The experience generated at IMSS may be helpful to other institutions, particularly those in developing countries.

More than 30 years ago it was demonstrated that significant numbers of primitive hematopoietic cells are found in umbilical cord blood (UCB).¹ It was not until the late 1980s, however, that UCB was recognized as a rich source of hematopoietic stem and progenitor cells for potential clinical use.² In keeping with this notion, the first hematopoietic cell transplant in which UCB was used as the source of hematopoietic cells, instead of marrow, was performed in Paris, France, in 1988.³ Over the past 15 years significant advances have been made both in the basic biology of UCB-derived stem and progenitor cells⁴ and in the clinical application of such cells.^{5,6}

ABBREVIATIONS: CBB = Cord Blood Bank; CFC(s) = colony-forming cell(s); IMSS = Mexican Institute of Social Security; UCB = umbilical cord blood; TNC(s) = total nucleated cell(s).

From the Umbilical Cord Blood Bank and the Department of Pediatric Hematology, La Raza Medical Center, IMSS, Mexico City; the Department of Hematology, Medical Specialties Hospital, IMSS, Puebla City; the Department of Hematology, Pediatrics Hospital, the Department of Hematology, Medical Specialties Hospital, and the Oncology Research Unit, Oncology Hospital, Siglo XXI Medical Center, IMSS, Mexico City; the Department of Pediatrics, Gabriel Mancera Hospital, IMSS, Mexico City, Mexico.

Address reprint requests to: Hector Mayani, PhD, National Medical Center, IMSS, Tallo 2, D-102, San Pablo Tepetlapa, Coyoacan, D.F. 04620, Mexico City, Mexico; e-mail: hmayaniv@prodigy.net.mx.

This study was supported by Grant 7204 from the National Council of Science and Technology (CONACYT, Mexico), and Grant 2005/2/1/365 from the Health Research Council of the Mexican Institute of Social Security (IMSS). Core support was provided by the IMSS Medical Division.

Received for publication April 18, 2007; revision received July 22, 2007, and accepted July 24, 2007.

doi: 10.1111/j.1537-2995.2007.01529.x

TRANSFUSION **, ** **

UCB transplantation has become a first-line therapy for specific hematologic conditions, particularly in pediatric patients.⁷ It is noteworthy, however, that during the past decade its application has expanded to adult patients through the use of large single-unit or double-unit transplants.^{5,8} Also during the past decade, single institutions, as well as multinational organizations and government regulatory agencies, have been actively involved in establishing regulatory issues regarding UCB collection, processing, and banking.^{9,10} Thus, the use of UCB transplantation for the treatment of hematologic, neoplastic, metabolic, and immune disorders continues to increase. Indeed, it is estimated that approximately 7,000 UCB transplants have been performed worldwide and that more than 200,000 UCB units are currently stored in UCB banks in several countries.¹¹

Most of the information reported to date regarding UCB banking and transplantation has come from developed countries (i.e., the United States, several European countries, Canada, Australia, and Japan).¹¹⁻¹⁴ In contrast, the experience generated in developing countries is still limited. There is no doubt, however, that UCB banking and transplantation are becoming more relevant in the latter countries due to both ease of procurement and cost. Indeed, large clinical programs involving UCB collection, processing, cryopreservation, and transplantation are already in progress in countries like China and Brazil.^{15,16} In Mexico, UCB banks have also been established, and UCB transplantation programs have already been initiated in different institutions, both public and private.¹⁷

The Mexican Institute of Social Security (IMSS) is a public, multicentric medical institution distributed throughout the Mexican territory, which covers approximately 50 percent of the nation's population (i.e., 50 million people). IMSS has created hematopoietic cell transplant programs in several cities and the total number of transplants being performed annually is between 160 and 180. The vast majority of hematopoietic transplants performed at IMSS use mobilized peripheral blood as the source of hematopoietic cells;^{18,19} however, due to both clinical and practical reasons, an increasing interest in UCB transplantation has been generated over the past few years. In January 2005, the IMSS Cord Blood Bank initiated its activities. To date, 360 UCB units have been collected; of those, 201 have been stored and 10 of them have been released for transplantation. Herein, we report the experience generated at IMSS during this initial 2-year period.

MATERIALS AND METHODS

The IMSS Cord Blood Bank (IMSS-CBB), located at La Raza Medical Center in Mexico City, initiated activities in January 2005. IMSS-CBB staff consists of seven full-time members and three part-time individuals and includes

physicians, laboratory technologists, nurses, and social workers.

Donor selection

Donors are full-term babies born to healthy, pregnant women receiving obstetric care at Tlatelolco Obstetrics Hospital and La Raza Obstetrics Hospital, IMSS. Both hospitals are located within a distance of 1 km from the UCB Bank. Informed consent was obtained from every woman after a brief overview on UCB transplantation was presented to her, including that UCB donation was voluntary, nonremunerated, a blood sample would be obtained for infectious disease screening, her medical history would be reviewed, and she would not be notified of the UCB status. All these procedures are based on those reported previously^{20,21} and were approved by the IMSS Medical Research Ethics Committee.

UCB units were considered for collection if: 1) the mother was between 18 and 40 years of age with no pregnancy complications; 2) the mother and her first-degree relatives did not have any hematologic disorder (including neoplasias or marrow failure syndromes), immune disorders, inherited coagulopathy, metabolic diseases, or thalassemia trait; 3) both parents had no history of high-risk sexual behavior and/or drug abuse; 4) there were no body piercing, tattoos, or blood transfusion within 1 year of the delivery; 5) the mother was negative for the presence of hepatitis B or C virus (as determined by a chemiluminescent immunoassay, Abbott Park, IL), syphilis, human immunodeficiency virus (HIV), and immunoglobulin M against cytomegalovirus; and 6) there was no sign of premature delivery, inborn abnormalities or asphyxia of the newborn.

Directed UCB banking was also considered when a family member had a disorder for which UCB transplant had proven to be beneficial. In case the prospective recipient died, the UCB donations would be released to the public inventory.

UCB collection and processing

Collections were performed in utero—in 80 percent of cases—and ex utero, outside the delivery room, in 20 percent of cases. These two procedures were performed as previously described.²¹ For both collection modalities, the umbilical cord was cleansed by wiping a large area around the intended insertion site with sterile gauze to clean up excess blood. Next, the cord was scrubbed for 30 seconds with topical antiseptic (i.e., povidone-iodine). The collector inserted the needle—of the attached collection set—into a visible placental vein. Collection usually took between 3 and 5 minutes. Either 150-mL blood bags (Grifols, Barcelona, Spain), containing 25 mL of CPD anti-coagulant, or 250-mL blood bags (Baxter Inc., Irvine, CA),

containing 35 mL of CPD anticoagulant, were used as the collection container. Samples of the cord blood product were removed from the tubing for further testing and retention. The UCB unit was then stored on wet ice for transport to the UCB Bank for processing.

UCB units of 50 mL or more (without anticoagulant) were processed within 24 hours of collection. Depletion of red blood cells (RBCs) and plasma, as well as white blood cell concentration, were performed based on the principles described by Rubinstein and coworkers²² and with a top-and-bottom system (Optipress II FDR 4920, Fenwall Division, Baxter Healthcare Corp., Lessines, Belgium). Precryopreservation samples were taken for laboratory studies. Total nucleated cell (TNC) count was conducted in a hematology analyzer (Cell Dyn 3700, Abbott). Cell viability was assessed by use of the trypan blue dye exclusion test. CD34⁺ cells were enumerated in a flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA). Hematopoietic progenitor cells capable of forming colonies in vitro (colony-forming cells [CFCs]) were assayed in methylcellulose-based semisolid cultures (MethoCult, StemCell Technologies Inc., Vancouver, British Columbia, Canada), as previously described.²³ Hematopoietic colonies were classified as follows: multipotent (CFU-MIX), colonies containing both erythroid and myeloid cells; and erythroid (CFU-E and BFU-E), clusters and colonies containing more than 20 hemoglobinized cells, grouped in one or several clusters. Myeloid colonies comprised the identifiable subpopulations of pure granulocytic colonies (CFU-G), pure macrophagic colonies (CFU-M), and colonies containing both granulocytes and macrophages (CFU-GM).

After processing, high-quality UCB units were selected according to specific, previously reported criteria,²¹ and were cryopreserved in an automated liquid nitrogen freezer, designated as the Bioarchive (Thermogenesis Corp., Rancho Cordova, CA), which computerizes the mechanical and record-keeping functions of freezing, storage and retrieval of UCB units. Cryopreservation was performed by adding a cryoprotectant solution of dimethyl sulfoxide (DMSO) and dextran 40 to the RBC-depleted cord blood unit. The final DMSO and dextran concentrations were 10 and 1 percent, respectively. All banked units were negative for fungal, aerobic and anaerobic microorganisms, and HIV virus. UCB thawing

and washing were performed according to previously reported methods.^{21,22} A polymerase chain reaction-based method (PEL-FREEZ SSP UniTray, Dynal Biotech, Brown, WI) was carried out for high-resolution typing of alleles in HLA-A, -B, and -DR loci and confirmatory typing for donor-recipient pairs before each transplant.

UCB transplantation

Patient treatment, according to the specific hematologic disease, and pretransplant conditioning regimens were performed according to well-established, institutionally approved protocols. UCB units were selected for transplantation based on TNC content and HLA match between donor and recipient. Neutrophil engraftment was defined as the first of 3 consecutive days at an absolute neutrophil count equal or higher than 500×10^3 per L.⁴ Platelet (PLT) engraftment, in contrast, was defined as the first of 7 consecutive days at an absolute PLT count equal or higher than 20×10^9 per L. Data were censored at the time of the last medical consultation, 7 to 10 days before submission of this study.

RESULTS

UCB banking

Based on the selection criteria described in the previous section, a total of 360 UCB units were collected from January 2005 to December 2006. A total of 156 units (43%) were discarded; among them, 136 were discarded before processing due to the following reasons: low volume (<50 mL), 98 units; birth-related newborn problems, 24 units; and clotted samples, 14 units. Twenty units were discarded due to viability of less than 90 percent (12 units) or damage during processing (8 units). The rest (204 units; 57% of the collected units) showed no problems before or during processing and were banked. Health counseling 6 months after birth indicated that one baby presented with congenital heart disease, one had hystiocytosis, and a third one had Prader-Willi syndrome; these 3 units were also discarded. Thus, the actual public inventory consisted of 201 units.

As shown in Table 1, the median volume obtained per UCB unit was almost 90 mL; with viability around

TABLE 1. Characteristics of the UCB units processed and stored at the IMSS-CBB from January 2005 to December 2006*

	Volume (mL)	Viability (%)	TNCs ($\times 10^9$)	CD34 ⁺ cells ($\times 10^6$)	CFCs ($\times 10^6$)
Mean \pm SD	97.1 \pm 40.6	95.7 \pm 2.7	0.98 \pm 0.40	3.93 \pm 2.47	1.87 \pm 1.31
Median	89.96	94.83	0.91	3.13	1.20
Range	50.71-149.16	90.6-99.0	0.36-2.66	0.22-21.9	0.08-7.75

* A total of 360 UCB units were collected during the period of study; 159 (44%) units were discarded because they did not meet the inclusion criteria. Results shown correspond to relative or absolute numbers per 201 UCB units considered.

95 percent and a median TNC number of 0.91×10^9 cells. The median frequency of CD34+ cells was 0.35 percent of the TNCs in each UCB unit, whereas CFCs corresponded to 0.13 percent. It is noteworthy that for every single variable analyzed, significant variability was observed between units. Among the total number of CFCs detected in each UCB unit, almost 60 percent corresponded to erythroid progenitors, whereas myeloid CFCs corresponded to 36 percent and multipotent progenitors corresponded to 6 percent (Fig. 1).

As mentioned previously, during this initial period, and to standardize our working methods and conditions, we included units with a minimum volume of 50 mL (without anticoagulant). The maximum volume collected was 149 mL (Table 1). Thus, we decided to evaluate the content of TNCs, CD34+ cells, and CFCs as a function of the volume collected. Among the 201 units processed and stored, 8 of them had a volume between 50 and 60 mL; 26 had 60 to 70 mL; 42 had 70 to 80 mL; 35 had 80 to 90 mL; 30 had 90 to 100 mL; and 60 had a volume of greater than 100 mL. Although great variability was seen, particularly for CD34+ cells, we observed a direct correlation between the volume of UCB collected per unit and the absolute numbers of nucleated cells (Fig. 2A), CD34+ cells (Fig. 2B), and CFC (Fig. 2C).

Quality control of UCB units released for transplantation

To date, 10 UCB units have been released for transplantation. One of them (released in May 2005) was banked as a directed UCB unit; the rest (released between April 2006 and December 2006) were part of the public inventory. From each one of the units, a pilot sample was processed to evaluate viability and TNC and CFC content after thaw. Unfortunately, we were unable to assess the content of CD34+ cells, due to the reduced cell number in the pilot samples. As shown in Table 2, a 20 percent loss in TNCs was observed after samples were thawed. In contrast, viability of the recovered cells was close to 100 percent, which was similar to the viability observed before cryopreservation. CFC growth was also similar to the one seen before the freezing procedure. It is noteworthy, however, that in one of the 10 units no colony growth was observed.

UCB transplantation

To date, seven patients have been transplanted at four different IMSS hospitals (three of them located in Mexico




Fig. 1. Frequency of myeloid, erythroid, and multipotent progenitor cells detected in 201 UCB units. Results shown correspond to mean \pm SD.

TABLE 2. QC analysis of the 10 UCB units released for transplantation

	Before cryopreservation*	After thaw†
TNCs	100%	82 \pm 2%
Viability	1.16 \pm 0.52 ($\times 10^9$)*	98 \pm 1%
CD34+ cells	95 \pm 2 (%)‡	NA
CFCs	100%	96 \pm 3%§
	1.17 \pm 0.66 ($\times 10^6$)*	

* Results shown correspond to values obtained after units were processed, just before they were cryopreserved.

† Results obtained from pilot samples from each one of the units, right after they were thawed; they represent mean \pm SD and correspond to relative values compared to those before cryopreservation. NA = not assessed.

‡ Actual values (per unit) observed before cryopreservation.

§ One of 10 units showed no CFC growth.

City and one in Puebla City, Puebla). Five of the patients were diagnosed as having acute lymphoid leukemia, one had acute myeloid leukemia, and one had Fanconi anemia. All but one were pediatric patients. Table 3 shows a summary of the transplants performed and the outcomes observed. The median number of nucleated cells infused per patient was 3.05×10^7 per kg (range, 1.21×10^7 - 6.71×10^7 /kg), and HLA match was four to five of six. Regarding this latter issue, it is noteworthy that at the moment of selecting the UCB units for transplantation, we placed major focus on compatibility at the level of the DR and A loci; indeed, in five cases, patient and donor were identical for the DRB1 locus; also in five cases patient




Fig. 2. Absolute numbers of TNCs (A), CD34+ cells (B), and CFCs (C) as a function of the volume collected per UCB unit. Results shown correspond to mean \pm SD. 50 to 60 mL, 8 units; 60 to 70 mL, 26 units; 70 to 80 mL, 42 units; 80 to 90 mL, 35 units; 90 to 100 mL, 30 units; greater than 100 mL, 60 units.

and donor were identical for the A locus. In contrast, in only one case, patient and donor were identical for the B locus, and in two cases, complete disparity between patient and donor was seen for such a locus. In the rest of cases, loci compatibility was observed for only one allele.

Two of the seven patients (Patients 1 and 4 in Table 3) showed no sign of engraftment and died on Days 30 and 29 posttransplant, respectively. The first one was a directed transplant, whereas the second (an adult patient) was an unrelated transplant in which 2 UCB units were used. It is noteworthy that in both cases, the nucleated cell number infused was less than 2.2×10^7 per kg. The other five patients showed engraftment and four of them were still alive and in good condition at the time this report was submitted (114-293 days after transplant).

Myeloid engraftment was observed between 7 and 54 days posttransplant, whereas PLT engraftment was detected on Days 12 to 87 posttransplant. It is noteworthy that in all five cases, the nucleated cell count infused was greater than 2.4×10^7 per kg. Interestingly, in one patient that received nonmyeloablative conditioning (Patient 6 in Table 3), engraftment was not observed after 4 weeks of receiving a single-unit transplant. During such a time, steady, albeit low, numbers of neutrophils (100-300 per μ L) were observed; however, a sudden decrease in absolute neutrophil count was detected by Day 30, suggesting that the hematopoietic activity (endogenous and/or from donor origin) was lost. A second transplant was performed 12 days later, which was a double-unit transplant; this resulted in myeloid and PLT engraftment, observed on Days 54 and 87 posttransplant, respectively, and the patient is currently in good condition. Among these five patients, only one showed Grade I acute graft-versus-host disease (GVHD; Patient 2 in Table 3); the rest showed no GVHD at all. Unfortunately, one of the patients in which engraftment was observed (Patient 7 in Table 3) died on Day +88 due to pneumonia.

TABLE 3. UCB transplants performed at IMSS: Characteristics of patients, grafts, and outcome

Patient	Age (years/sex/weight) (kg)	Diagnosis	HLA	TNCs/kg ($\times 10^7$)	Days to ANC count >500/ μ L	Days to APC count >20 $\times 10^9$ /L	Status
1	9/male/40	FA	4/6	1.21	NE	NE	Dead
2	5/male/20	ALL	5/6	3.50	19	41	292*
3	3/male/14	ALL	5/6	6.71	37	43	293*
4	23/female/48	ALL	4/6†	1.02	NE	NE	Dead
			4/6†	1.13			
5	3/male/17	ALL	5/6	6.29	7	12	264*
6	16/male/52	AML	4/6	3.25	NE	NE	30‡
			4/6†	1.55	54	87	114*
			4/6†	1.35			
7	7/female/21	ALL	4/6	2.41	43	56	Dead

* Days from transplant to the time of manuscript submission; patient is alive in complete remission.

† Double-unit transplant.

‡ Hematopoietic activity was lost on Day 30 posttransplant and a second transplant was performed.

ANC = absolute neutrophil count; APC = absolute PLT count; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia;

FA = Fanconi anemia; NE = no engraftment.

DISCUSSION

During the past decade UCB banking and transplantation have increased in a significant manner worldwide. This is particularly true for developed countries. In developing countries, however, the experience is still limited. Herein, we report the results of the UCB banking and transplantation program at the IMSS (the largest public medical institution in Mexico, covering approx. 50 million people), which was initiated in January 2005.

Donor selection criteria used at our institution were based on those reported previously by different international organizations^{10,21} and were also very similar to those used by the Guangzhou group.¹⁵ During this initial 2-year period, 360 UCB units were collected. Of those, 204 (57%) met the inclusion criteria and were stored. Such a proportion was similar or slightly higher than those reported by different institutions,^{15,21,24} which indicates that our acceptance rate is within the standard range. A total of 204 UCB units in a 2-year period is certainly a low number when compared to those reported by other groups—for example, the Guangzhou group has banked 4476 units in a 7-year period (639 units per year, in average),¹⁵ while the Barcelona Cord Blood Bank has stored 7011 units during 11 years (637 units per year, on average; Netcord Newsletter, January 2007)—however, it is important to consider that this is the initial phase of our program; we have evidence that this number will increase significantly in the following years, as our donor recruitment and UCB collection program improves. Three additional units were discarded 6 months after being banked due to health problems and abnormalities of the donors not evident at birth. Thus, the actual public inventory consisted of 201 units (as of December 31, 2006).

During this initial period, UCB units containing a minimum of 50 mL (without anticoagulant) were considered for processing. Under the collection conditions and

standards described here, the volume obtained, as well as the values of TNC, viability, CD34+ cells, and CFCs were within the range reported previously by different groups from the United States of America.¹³ This suggests that our technical procedures were adequate. As expected, we found a direct correlation between the volume collected and TNC, CD34+ cell, and CFC numbers; it is noteworthy, however, that a great variability was observed, which is also in keeping with previous reports.^{13,24,25} Such variability was particularly evident for CD34+ cells and CFCs.

Based on the experience generated in some institutions, it has been recommended that UCB units must have a minimum of 0.8×10^9 nucleated cells to be stored.²¹ In our experience, only 49 percent of the UCB units banked achieved such a cell number. According to such a recommendation, and considering the results of the present study, from now on only UCB units with a minimum volume of 70 mL will be processed at the IMSS-CBB.²⁶ We anticipate that most of these units will meet the required cell number (0.8×10^9 nucleated cells) and will be stored for their use in single-unit transplants or in double-unit transplants, which are being performed more frequently both for adult patients and for large children.^{27,28}

In terms of the progenitor cells detected by colony assays, we observed that the majority of them corresponded to erythroid progenitors, followed by myeloid and multipotent cells. These proportions were similar to those reported previously by our own group and others,^{23,25} and confirm that, in contrast to marrow, where myeloid progenitors are most abundant, erythroid progenitors comprise the majority of CFC in UCB.

Among the 201 units banked, 10 of them have been released for transplantation. This indicates a consumption rate of 5 percent, which compares favorably to those reported by other centers^{9,15} (Netcord Newsletter, January 2007). Quality control (QC) tests were performed in samples from all 10 units right after they were thawed. We

1 observed a 15 to 25 percent loss in TNCs; in contrast,
2 viability and CFC levels were not affected. These results
3 are in agreement with those reported by Laroche and col-
4 leagues,²⁹ who observed that after thaw, TNC numbers
5 were reduced by 20 percent, whereas no significant
6 changes occurred in cell viability or in the content of
7 CD34+ cells and CFCs.

8 During this initial period (January 2005-December
9 2006), seven patients received transplants, receiving UCB
10 units from the IMSS-CBB. Two of them showed no engraft-
11 ment and died 29 and 30 days after transplant. In contrast,
12 engraftment was observed in five patients; four of them
13 are still alive and in complete remission 114 to 293 days
14 posttransplant. Although one patient showed a sustained
15 engraftment, he died on Day +88 due to pneumonia. It is
16 noteworthy that in those patients that showed no engraft-
17 ment the nucleated cell dose infused was 1.21×10^7 to
18 2.15×10^7 cells per kg of body weight (even though one of
19 them received a double-unit transplant), whereas the
20 patients that showed engraftment received a median of
21 $3.38 (2.41-6.71) \times 10^7$ cells per kg of body weight. Accord-
22 ing to the standards suggested by some authors²⁸ and at
23 different international forums, 2.0×10^7 nucleated cells
24 per kg of body weight should be the minimum cell dose
25 for a UCB transplant. Some researchers further suggest
26 that such a minimum cell dose should be raised to
27 2.5×10^7 cells per kg of body weight.³⁰ Thus, confirming
28 these notions, in the present study we observed a correla-
29 tion between cell dose and engraftment.

30 It has been previously demonstrated that myeloid
31 and PLT engraftment in UCB transplants are delayed,
32 compared to those observed in bone marrow or mobilized
33 peripheral blood transplants,²⁸ and this seems to be due to
34 a reduced number of stem and progenitor cells in UCB
35 units. In our experience, myeloid engraftment occurred 7
36 to 54 days posttransplant, whereas PLT engraftment was
37 detected on Days 12 to 87 posttransplant; these results are
38 comparable to those reported by other groups.^{15,28}

39 In trying to increase cell dose, especially for adult
40 patients and large children, double-unit transplants are
41 being performed more frequently.^{28,31} In those studies, it
42 has been consistently observed that only 1 of the 2 units
43 administered is sustained long-term, whereas the other is
44 somehow lost. Interestingly, the "winning" unit could not
45 be predicted from its infused cell dose, the degree of HLA
46 disparity with the recipient, ABO group compatibility, sex
47 match, or the order in which each one of the units was
48 infused.^{27,28} In the present study, two of the patients
49 received double-unit transplants. One patient died
50 29 days after transplant without showing any engraft-
51 ment, whereas the other is still alive (114 days posttrans-
52 plant) and in clinical remission. At the moment, however,
53 we have not assessed chimerism in this latter patient, so
54 we do not know whether both units are still present in the
55 patient's marrow or only 1 unit has engrafted.

56 Another approach that has been suggested to
57 increase cell dose in UCB transplants is the infusion of ex
58 vivo expanded stem and progenitor cells.^{28,31} The studies
59 reported to date have shown that although infusion of
60 expanded cells into patients did not significantly alter
61 myeloid, erythroid, or PLT engraftment, this procedure is
62 feasible and safe, and thus it may be used in particular
63 cases.^{32,33} We have already developed strategies for the ex
64 vivo expansion of UCB-derived progenitor cells^{34,35} and
65 will soon start working on protocols aimed at the clinical-
66 scale expansion of UCB cells under good manufacturing
67 practices.

68 Finally, it is important to point out that to establish
69 the UCB bank at our institution we had to overcome
70 both economic and cultural issues; it took more than
71 20 months from the time the project was presented to the
72 IMSS authorities to the time the UCB bank initiated activi-
73 ties. The cost of establishing the bank was covered by the
74 IMSS itself, together with the National Council of Science
75 and Technology (CONACYT, Mexico); these institutions
76 covered 65 and 35 percent of the total cost, respectively.
77 In cultural terms, this initial 2-year period was difficult
78 because of the lack of knowledge among the general
79 population, regarding UCB banking and transplantation.
80 Thus, obtaining informed consent from the mothers was
81 difficult at the beginning. This is an area that we have
82 worked out, however, by giving talks at different IMSS hos-
83 pitals and by preparing informative brochures. It is also
84 important to mention that we are currently working on
85 the analysis of the ethnicity and HLA profiles of the units
86 banked to compare them to registries from other coun-
87 tries (e.g., NMDP).

88 Although the experience presented herein is still
89 limited, the results obtained during this initial period
90 are encouraging and indicate that the UCB banking
91 and transplantation program at IMSS will help to
92 improve already existing hematopoietic cell transplant
93 programs in Mexico. Evidently, long-term assessments of
94 our UCB program will be needed to evaluate its actual
95 impact. The experience generated at IMSS may be
96 helpful to other institutions, particularly those in devel-
97 oping countries.

98 ACKNOWLEDGMENTS 99

100 Drs Patricia Flores, Guadalupe Carrillo, Roberto Bernaldez, and
101 Gamaliel Benitez are thanked for their help in data collection,
102 logistic support, and useful comments.

103 REFERENCES 104

- 105 1. Knudtzon S. In vitro growth of granulocyte colonies from
106 circulating cells in human cord blood. *Blood* 1974;43:357-
107 61.

NOVELO-GARZA ET AL.

- 1 2. Broxmeyer HE, Douglas GW, Hangoc G, Boyse E. Human
2 umbilical cord blood as a potential source of transplant-
3 able hematopoietic stem/progenitor cells. *Proc Natl Acad*
4 *Sci U S A* 1989;86:3828-32.
- 5 3. Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS,
6 Douglas GW, Devergie A, Esperou H, Thierry D, Socie G,
7 Lehn P. Hematopoietic reconstitution of a patient with
8 Fanconi anemia by means of umbilical cord blood from an
9 HLA-identical sibling. *N Engl J Med* 1989;321:1174-8.
- 10 4. Mayani H, Lansdorp PM. Biology of human umbilical cord
11 blood-derived hematopoietic stem/progenitor cells. *Stem*
12 *Cells* 1998;16:153-65.
- 13 5. Ballen KK. New trends in umbilical cord blood transplanta-
14 tion. *Blood* 2005;105:3786-92.
- 15 6. Gluckman E. Cord blood transplantation. *Biol Blood*
16 *Marrow Transplant* 2006;12:808-12.
- 17 7. Gluckman E. Current status of umbilical cord blood
18 hematopoietic stem cell transplantation. *Exp Hematol*
19 2000;28:1197-205.
- 20 8. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA,
21 Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE,
22 Rubinstein P, Kurtzberg J. Hematopoietic engraftment and
23 survival in adult recipients of umbilical cord blood from
24 unrelated donors. *N Engl J Med* 2001;344:1815-22.
- 25 9. Wernet PW. The international NETCORD foundation. In:
26 Broxmeyer HE, editor. *Cord blood: biology, immunology,*
27 *banking and clinical transplantation.* Bethesda: American
28 Association of Blood Banks; 2004. p. 429-35.
- 29 10. NetCord/Fact. International standards for cord blood col-
30 lection, processing, testing, banking, selection and release.
31 2nd ed. Omaha: FACT; 2001.
- 32 11. Rubinstein P. Why cord blood? *Hum Immunol* 2006;67:
33 398-404.
- 34 12. Rebullá P. Cord blood banking 2002. *Transfusion* 2002;42:
35 1246-8.
- 36 13. Lasky LC, Lane TA, Miller JP, Lindgren B, Patterson HA,
37 Haley NR, Ballen K. In utero or ex utero cord blood
38 collection: which is better? *Transfusion* 2002;42:1261-84.
- 39 14. McCullough J, McKenna D, Kadidlo D, Schierman T,
40 Wagner J. Issues in the quality of umbilical cord blood
41 stem cells for transplantation. *Transfusion* 2005;45:832-41.
- 42 15. Wu JY, Liao C, Xu ZP, Chen JS, Gu SL, Huang YN, Li Y, Tang
43 XW, Yang X, Tang PH, Tsang KS. Banking and transplanta-
44 tion of umbilical cord blood in Guangzhou. *China Cyto-*
45 *therapy* 2006;8:488-97.
- 46 16. de Medeiros CR, Bitencourt MA, Zanis-Neto J, Maluf EC,
47 Carvalho DS, Bonfim CS, Funke VM, Setubal DC, Farah N,
48 Pasquini R. Allogeneic hematopoietic stem cell transplan-
49 tation from an alternative stem cell source in Fanconi
50 anemia patients: analysis of 47 patients from a single insti-
51 tution. *Braz J Med Biol Res* 2006;39:1297-304.
- 52 17. Mancias-Guerra C, Ruiz-Delgado GJ, Manzano C, Diaz-
53 Hernandez MA, Tarin-Arzaga LC, Gonzalez-Llano O, Cal-
54 daron E, Gomez-Almaguer D, Ruiz-Arguelles G. Umbilical
55 cord blood transplantation using non-myeloablative
conditioning: the Mexican experience. *Hematology* 2006;
11:355-9.
18. Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado
E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont
M, Estrada-García I, Montiel-Cervantes L, Tripp-Villanueva
F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza
JR, Mayani H. Clinical relevance of NK, NKT and dendritic
cell dose in patients receiving G-CSF-mobilized peripheral
blood allogeneic stem cell transplantation. *Ann Hematol*
2006;85:113-20.
19. Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado
E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont
M, Estrada-García I, Mayani H, Montiel-Cervantes L,
Tripp-Villanueva F, Ayala-Sánchez M, García-León LD,
Borbolla-Escoboza JR. Peripheral blood mobilization of
different lymphocyte and dendritic cell subsets with the
use of intermediate doses of G-CSF in patients with non-
Hodgkin's lymphoma and multiple myeloma. *Ann*
Hematol 2006;85:308-14.
20. Vawter DE, Rogers-Chrysler G, Clay M, Pittelko L,
Therkelsen D, Kim D, McCullough J. A phased consent
policy for cord blood donation. *Transfusion* 2002;42:
1268-74.
21. Chrysler GR, McKenna DH, Schierman T, Kadidlo D, Askari
S, Miller J, Clay ME, McCullough J. Umbilical cord blood
banking. In: Broxmeyer HE, editor. *Cord blood: biology,*
immunology, banking and clinical transplantation.
Bethesda: American Association of Blood Banks; 2004.
p. 219-57.
22. Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW,
Migliaccio G, Migliaccio AR, Taylor PE, Stevens CE. Pro-
cessing and cryopreservation of placental/umbilical cord
blood for unrelated bone marrow reconstitution. *Proc Natl*
Acad Sci U S A 1995;92:10119-22.
23. Mayani H, Gutierrez-Rodriguez M, Espinoza L, Lopez-
Chalini E, Huerta-Zepeda A, Flores E, Sanchez-Valle E,
Luna-Bautista F, Valencia I, Ramirez OT. Kinetics of
hematopoiesis in Dexter-type long-term cultures estab-
lished from human umbilical cord blood cells. *Stem Cells*
1998;16:127-35.
24. Tamburini A, Malerba C, Picardi A, Amadori S, Calugi A.
Placental/umbilical cord blood: experience of St. Eugenio
Hospital collection center. *Transplant Proc* 2005;37:
2670-2.
25. Bornstein R, Flores AI, Angeles-Montalban M, Del Rey MJ,
De la Serna J, Gilsanz F. A modified cord blood collection
method achieves sufficient cell levels for transplantation in
most adult patients. *Stem Cells* 2005;23:324-34.
26. Novelo-Garza BA, Benitez-Arvizu G, Cortes-Marquez S,
Sanchez-Cañas JA, Franco-Gutierrez E, Arellano-Ocampo
JS, Guerra-Marquez A. Es importante el volumen en la
recolección de sangre de cordón umbilical? *Rev Med Inst*
Mex Seguro Soc 2006;44 Suppl 2:107-10.
27. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double
chimera after the transplantation of umbilical cord blood

- 1 from two partially matched unrelated donors. *N Engl J*
 2 *Med* 2001;344:1870-1.
- 3 28. Hough RE, Barker JN, Wagner JE. Innovation in umbilical
 4 cord blood transplantation. In: Broxmeyer HE, editor. *Cord*
 5 *blood: biology, immunology, banking and clinical trans-*
 6 *plantation*. Bethesda: American Association of Blood
 7 Banks; 2004. p. 337-79.
- 8 29. Laroche V, Mckenna DH, Moroff G, Schierman T, Kadidlo
 9 D, McCullough J. Cell loss and recovery in umbilical cord
 10 blood processing: a comparison of postthaw and postwash
 11 samples. *Transfusion* 2005;45:1909-16.
- 12 30. Rubinstein P, Stevens CE. Placental blood for bone
 13 marrow replacement: the New York Blood Center's
 14 program
 15 and clinical results. *Baillieres Clin Haematol* 2000;13:
 16 565-84.
- 17 31. Brunstein CG, Setubal DC, Wagner JE. Expanding the role
 18 of umbilical cord blood transplantation. *Br J Haematol*
 19 2007;137:20-35.
- 20 32. Shpall EJ, Quinones R, Giller R, Zeng C, Barón AE, Jones
 21 RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ,
 Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E,
 Malcom J, Ward W, McNiece IK. Transplantation of ex vivo
 expanded cord blood cells. *Biol Bone Marrow Transplant*
 2002;8:368-76.
33. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL,
 Driscoll TA, Howrey R, Chao N, Douville J, Burhop S, Fu P,
 Kurtzberg J. Augmentation of umbilical cord blood (UCB)
 transplantation with ex vivo-expanded UCB cells: results of
 a phase I trial using the AastromReplicell System. *Blood*
 2003;101:5061-7.
34. Flores-Guzmán P, Gutiérrez-Rodríguez M, Mayani H. In
 vitro proliferation, expansion and differentiation of a
 CD34+ cell-enriched hematopoietic cell population from
 human umbilical cord blood in response to recombinant
 cytokines. *Arch Med Res* 2002;33:107-14.
35. Flores-Guzman P, Martinez-Jaramillo G, Montesinos JJ,
 Valencia I, Mayani H. Growth kinetics of progenitor cell-
 enriched hematopoietic cell populations in long-term
 liquid cultures under continuous removal of mature cells.
Cytotherapy 2006;8:299-307. ■

SNP Best-set Typesetter Ltd.	
Journal Code: TRF	Proofreader: Emily
Article No: 01529	Delivery date: 11 October 2007
Page Extent: 9	

AUTHOR QUERY FORM

Dear Author,

During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these matters and return this form with your proof.

Many thanks for your assistance.

Query References	Query	Remark
q1	Au: Please verify affiliations.	
q2	Au: Please verify city name that has been added for Baxter Healthcare Corp.	
q3	Au: Please verify generic description of Cell Dyn 3700 that has been added.	
q4	Au: Cell counts have been converted to scientific notation. Please verify.	
q5	Au: 4-5/6 has been changed to four to five of six . Is this as meant?	